Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

From Your Site Articles
TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
Enrique Gomez joins the Houston Innovators Podcast to discuss Houston as an oncology innovation hub. Photo via TMC.edu

How Houston is emerging as a leader for oncology innovation, according to this expert

Houston innovators podcast episode 114

Houston is currently establishing itself as a hub for health care innovation — and Enrique Gomez should know. He's worked in the field of biopharmaceuticals across the continent.

As entrepreneur in residence at Texas Medical Center Innovation's Accelerator for Cancer Therapeutics, he works with early stage startups and researchers. However, for decades he's worked in a much later stage of drug development, holding leadership positions at Takada in Latin America and Shire in Boston.

"Texas is very well recognized for cancer therapeutics," Gomez says on this week's episode of the Houston Innovators Podcast. "There's a lot of research going on. These researchers are looking at every angle — every possible strategy to tackle cancer."

At ACT, Gomez connects the startups or instigators with the resources they need to get their life-saving solutions to market. With cancer, there's not one thing that's going to work. There have to be options for treating cancer.

"Cancer is very heterogeneous. Not one strategy will be the single silver bullet to overcome the disease," Gomez says. "We are talking about personalized medicine. Every person is different and every cancer in every patient is different. It will require a number of approaches to overcome the health situation."

Thankfully, through TMC's ACT and the numerous research institutions working on the future of oncology, Houston's a great spot to move that needle.

"Houston is a place where everyone looks at when it comes to novel research and approaches to treating cancer," Gomez says. "The landscape here is going to be accelerated because we see much more collaboration between the founding institutions — and that's a very important element of growth. Houston has no comparison to any other place in terms of what's going on here and the level and quality of research."

He shares more on how COVID-19 has affected drug development and research — as well as what's next for his own career — on the podcast. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston investor on why 2025 will be the year of exits

houston innovators podcast episode 270

Samantha Lewis will be the first to admit that the past few years have been tough on startups and venture capital investors alike. However, as she explains on the Houston Innovators Podcast, the new year is expected to look very different.

"We're super excited going into 2025," says Lewis, who is a partner at Houston-based VC firm Mercury. "For us, 2024 was a year of laying a lot of groundwork for what we believe is going to be a massive year of startup exits and liquidity for the venture ecosystem. We've been hard at work making sure our companies are prepared for that."

Mercury, in fact, has already gotten a taste, with three of its portfolio companies celebrating exits — all with Houston roots. Fintech platform Brassica was acquired by BitGo in February, and Apparatus, founded as Topl in Houston, was acquired early last year. The third deal has yet to be announced publicly.

And it's just getting started, Lewis says. She explains that all of the companies in Mercury's portfolio that are promising — albeit not break-out, to-be-billion-dollar companies — are going to have opportunities to sell in 2025 and 2026.

"What we've started to do — and I encourage everyone to do this if you're working on a startup — is just start to just engage with strategic buyers, investment bankers, and people you think might be a great fit to buy your company," Lewis says, "because we really think that the next few years will be the best liquidity years we've seen in a really long time. And if you're not ready for it, you're going to miss the boat."

In addition to sharing her advice to get "exit preparedness," Lewis explains some specific tech trends she's keeping an eye on in Mercury's "power theme," which she works on directly. This encompasses fintech, blockchain, web3 and more.

SpaceX loses mega rocket in latest thrilling Starship test flight

Testing

SpaceX launched its Starship rocket on its latest test flight Thursday, but the spacecraft was destroyed following a thrilling booster catch back at the pad.

Elon Musk’s company said Starship broke apart — what it called a “rapid unscheduled disassembly." The spacecraft's six engines appeared to shut down one by one during ascent, with contact lost just 8 1/2 minutes into the flight.

The spacecraft — a new and upgraded model making its debut — was supposed to soar across the Gulf of Mexico from Texas on a near loop around the world similar to previous test flights. SpaceX had packed it with 10 dummy satellites for practice at releasing them.

A minute before the loss, SpaceX used the launch tower's giant mechanical arms to catch the returning booster, a feat achieved only once before. The descending booster hovered over the launch pad before being gripped by the pair of arms dubbed chopsticks.

The thrill of the catch quickly turned into disappointment for not only the company, but the crowds gathered along the southern tip of Texas.

“It was great to see a booster come down, but we are obviously bummed out about [the] ship,” said SpaceX spokesman Dan Huot. “It’s a flight test. It’s an experimental vehicle," he stressed.

The last data received from the spacecraft indicated an altitude of 90 miles and a velocity of 13,245 mph.

Musk said a preliminary analysis suggests leaking fuel may have built up pressure in a cavity above the engine firewall. Fire suppression will be added to the area, with increased venting and double-checking for leaks, he said via X.

The 400-foot rocket had thundered away in late afternoon from Boca Chica Beach near the Mexican border. The late hour ensured a daylight entry halfway around the world in the Indian Ocean. But the shiny retro-looking spacecraft never got nearly that far.

SpaceX had made improvements to the spacecraft for the latest demo and added a fleet of satellite mockups. The test satellites were the same size as SpaceX’s Starlink internet satellites and, like the spacecraft, were meant to be destroyed upon entry.

Musk plans to launch actual Starlinks on Starships before moving on to other satellites and, eventually, crews.

It was the seventh test flight for the world’s biggest and most powerful rocket. NASA has reserved a pair of Starships to land astronauts on the moon later this decade. Musk’s goal is Mars.

Hours earlier in Florida, another billionaire’s rocket company — Jeff Bezos’ Blue Origin — launched the newest supersized rocket, New Glenn. The rocket reached orbit on its first flight, successfully placing an experimental satellite thousands of miles above Earth. But the first-stage booster was destroyed, missing its targeted landing on a floating platform in the Atlantic.

Houston private equity firm beats target on first investment fund

fresh funds

Houston-based private equity firm Sallyport has raised $160 million for its first investment fund, exceeding the target amount by $10 million.

The Sallyport Partners Fund focuses primarily on investments in founder- and family-owned businesses, corporate carve-outs and startups in various industries.

The firm’s chairman, Doug Foshee, seeded the fund. He and managing partners Kyle Bethancourt and Ryan Howard started the firm in 2023.

“Sallyport Partners Fund was created to utilize the proven processes our team has developed over time to generate value for like-minded investors on a larger and more impactful scale,” Foshee says in a news release.

Investors in the Sallyport fund include entrepreneurs, business executives and influential Texas families. Aside from Foshee, names of the fund’s investors weren’t disclosed.

“We are deeply committed to working hand-in-hand with management teams to drive transformative growth and generate long-term value,” says Bethancourt. “Our operational capabilities are forged from decades of firsthand experience leading, investing in, and building thriving businesses from the ground up. We have a unique appreciation for the management team’s perspective because we’ve been in their shoes.”

Those shoes have covered some pretty impressive ground:

  • Foshee is former chairman, president, and CEO of Houston-based El Paso Corp., which owned and operated a 44,000-mile natural gas pipeline network. In 2012, El Paso merged with Houston-based pipeline company Kinder Morgan in a multibillion-dollar deal.
  • Before Sallyport, Bethancourt was a vice president in the credit division of Blackstone, an investment powerhouse with more than $1 trillion in assets under management. Earlier, he worked at D.E. Shaw & Co., a New York City-based hedge fund with more than $65 billion in assets under management.
  • Before Sallyport, Howard worked at Platform Partners, a Houston-based private equity firm. Earlier, he worked for the natural resources arm of investment banking giant Goldman Sachs.
View All Listings